- We were inspired by recent visits from two of our patients who are participating in our Phase 1 trials. They shared with us their experiences as brain cancer survivors and how they are enjoying life.
- Our potential registrational Phase 2/3 Toca 5 trial is enrolling brain cancer patients at 46 sites in the U.S. and Canada.
- Our science and progress has been reported by the media, including multiple TV segments including CBS, Fox, and NBC and an article featured in U.S. News & World Report.
- We launched a new blog that provides tips for brain cancer patients and their caregivers, authored by well-known patient advocate Mary Lovely, Ph.D., RN, CNRN.
- Tocagen scientists published three peer-reviewed articles, including our first clinical paper, which was selected for the cover of the prestigious journal Science Translational Medicine.
- Our scientists presented new preclinical and clinical data at key conferences, including ASCO, ASGCT and AACR.
Stay tuned for more updates, and we are grateful for your continued support in our fight against cancer!
The Tocagen team.
We were honored to have patient Greg, wife Sarah and adorable baby Colton stop by Tocagen’s headquarters. His key message: Participation in clinical trials is vital to help advance research. Without research, progress can’t be made, and, importantly, it gives patients hope.
Patient Max and his wife Marilyn were also able to visit Tocagen, where he shared his progress since enrolling in the trial and life today with his grandchildren and new puppy affectionately called “Toca”.
Toca 5 Trial Now Actively Recruiting Patients at 42 Locations Across North America!
We’ve been working hard to expand the Toca 5 study, and are pleased to announce that the trial is actively recruiting patients at 42 leading brain cancer centers across the U.S. and Canada. A full list of open sites can be found here. We will continue to focus on opening additional sites in the months ahead.
Tocagen Science and Progress highlighted by the Media
Patient Greg describes his latest MRI results and Dr. Mikkelsen explains the Toca 5 study.
Patient Donna and her loving husband tell us about their life after receiving Tocagen’s treatment; Dr. Landolfi discusses Toca 511 & Toca FC. Watch the news segments: CBS New York TV and New Jersey TV.
Patient Max and his wife Marilyn update us on their lives today, including new puppy “Toca” – named after Tocagen! Also, Dr. Carter provides more context for Tocagen’s survival data. Watch the news segments: Fox news, NBC news, CBS San Diego, and CW6 San Diego.
Headline: Brain cancer treatment shows promise in early trial.
Headline: Retroviral Replicating Vector that delivers cytosine deaminase to cancer cells active in rGBM.
Front page headline: Viral/chemotherapy combo fights brain cancer.
Headline: Tumor-killing virus nearly doubles survival time of brain cancer patients.
New Patient & Caregiver Blog
Tocagen has launched a blog to provide brain cancer patients and caregivers with tips and resources. Authored by Dr. Lovely, our patient support and liaison, we hope these blogs will provide helpful information and address the needs of patients fighting brain cancer. Our latest posts follow:
Have an idea for a post? We’d love to hear it. Email Dr. Lovely at firstname.lastname@example.org with more info about your idea.
Tocagen Article Selected for the Cover of Science Translational Medicine
Data showing Toca 511 & Toca FC extended survival in patients with recurrent brain cancer compared to an external control were featured on the cover of Science Translational Medicine. This important milestone was Tocagen’s first clinical manuscript and was widely covered by the media, including national, industry and local outlets, who also profiled patients doing well on the trial. We even made it into Google’s Top Stories! The study was also shared on social media, including by the National Cancer Institute. The abstract of the paper, authored by Timothy Cloughesy, M.D., of University of California, Los Angeles, can be found here.
Additional Tocagen Data Publishes
Kader Yagiz, Ph.D., and co-authors, published preclinical research in Neuro-Oncology demonstrating that Toca 511 & 5-FC in combination with lomustine showed anticancer activity and immune activation against tumors. Read the abstract.
Amy Lin, Ph.D., and co-authors, reported new data about the stability of Toca 511 viral replication in Human Gene Therapy Methods. Read the abstract.
Social Media Buzz – Tocagen Goes Viral!
We continue to see high levels of engagement on social media, particularly on our Facebook and Twitter channels, from patients, caregivers and other members of the brain cancer community. Our Facebook posts alone have reached over 139,000 people since Feb 2016, and were liked by over 19,000 people! This is helping boost awareness about our clinical trials and support our patient recruitment efforts. Notably, followers have been sharing the posts with their networks and alerting brain cancer patients who may be candidates for the Toca 5 study. If you have not seen our social media pages, click on the icons!
Our Toca 511 & Toca FC animation video on YouTube is now available with subtitles in 8 different languages: English, Spanish, French, Hebrew, Arabic, German, Japanese and Korean! To select your preferred language, click here, select settings/subtitles/and select your language. Not following us yet? Connect with us on Twitter or Facebook!
Out and About: Tocagen Execs Present Data, Speak on Panels
Tocagen’s scientists and management team presented data and participated on panels at several conferences:
- 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
- 17th Biennial Canadian Neuro-Oncology (CNO) Meeting
- Immunology 2016: American Association of Immunologists (AAI) Annual Meeting
- 84th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
- American Association for Cancer Research (AACR) Annual Meeting
- Alliance for Cancer Gene Therapy (ACGT) Scientific Symposium
- American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting
- 9th Annual Oncology Commercialization & Market Access Meeting
- 2016 Cancer Advance Boston Conference
- 2016 Phacilitate Oncology Leaders Forum
Our VP of clinical development and medical affairs, Asha Das, M.D., and fellow panelists, including an executive from Bristol-Myers Squibb, discussed the important role of viruses in activating the immune system against tumors at the 2016 BIO International Convention. She was also selected by BIO to participate in a video interview by former CNBC reporter Mike Huckman where she discussed our latest trial results and ongoing study (pictured at right; video here).
Our CEO, Harry Gruber, M.D., spoke on a panel at Boston CEO 2016, where he also announced publication of data in Science Translational Medicine. Dr. Gruber also discussed “magic bullets, moonshots and more” at Cavendish Global’s California Global Health Impact Forum (pictured right).
Nick A. Boyle, Ph.D., VP of business development and marketing presented at the 2016 BIO International Convention.
Other News to Note
RiboMed Biotechnologies, Inc. and Tocagen Inc. announced a collaboration to analyze potential epigenetic prognostic and predictive markers in our clinical trials. Read the news release. Read the scientific article.
Tocagen is looking for the best and the brightest to join our team. View current job openings.
Join Tocagen at These Upcoming Events
Ongoing Clinical Trials
Learn more about our clinical trials.
Patient Support and Liaison: Mary Lovely, email@example.com, (858) 412-8473
Media Inquiries: Monica May, firstname.lastname@example.org
Investor Inquiries: Dennis Berman, email@example.com
Other Inquiries: Nicholas Boyle, firstname.lastname@example.org
Forward-Looking Statements: Tocagen makes forward-looking statements herein or in connection herewith that involve potential risks and uncertainties. These statements include statements regarding Tocagen’s expectations, hopes, beliefs, intentions, or strategies regarding the future. These forward statements also include statements regarding (i) the success of Tocagen’s anticipated research and development efforts, including pre-clinical studies and the timing of, the government regulation of, and degree of safety and efficacy in, clinical trials, and Tocagen’s future financial results, (ii) Tocagen’s future financing assumptions, (iii) Tocagen’s market position and the size and competitiveness of its market for its anticipated products and services, and (iv) Tocagen’s ability to develop future products and services. It is important to note that Tocagen’s actual results could differ materially from those in such forward-looking statements.
Neither this newsletter nor any link in this Newsletter to other information, including but not limited to videos prepared by third parties, constitutes an offer or invitation for the sale or purchase of securities. The information set out herein and therein is preliminary and should not be relied upon for any purpose. Tocagen does not make any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein and therein and shall not have any liability for such information.